drugset / Trial / NCT02499978
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Phase 2/3
Withdrawn
Stanford University
Janssen Scientific Affairs, LLC · collabUniversity of Colorado, Denver · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
Timeline
- Start
- 2016-05
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobicistat | Small molecule | 150 mg | — |
| Subject | Darunavir | Small molecule | 800 mg | — |
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |